Cyclerion Therapeutics

64 articles about Cyclerion Therapeutics

• Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - June 01, 2023

  6/1/2023

  Cyclerion Therapeutics, Inc. announced that it has received a formal notice from The Nasdaq Stock Market stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550, and that Cyclerion is in compliance with all applicable listing standards.

• Cyclerion Announces Reverse Stock Split - May 15, 2023

  5/15/2023

  Cyclerion Therapeutics, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023.

• Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

  5/11/2023

  Cyclerion Therapeutics, Inc. announced that it has signed a definitive agreement with a new private company to sell two of its sGC stimulator assets in exchange for cash and equity ownership.

• Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

  5/11/2023

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.

• Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

  4/3/2023

  Cyclerion Therapeutics, Inc. announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members, has reviewed a non-binding proposal received on March 17, 2023 from an entity formed by investors that include the Company’s Chief Executive Officer, to purchase the Company’s zagociguat and CY3018 assets.

• Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

  3/27/2023

  Cyclerion Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases.

• Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

  3/22/2023

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program.

• 

  BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus

  10/7/2022

  BioMarin Pharmaceuticals announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.

• Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

  10/6/2022

  Cyclerion Therapeutics, Inc. announced its mitochondrial disease-focused corporate strategic plan.

• Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

  8/9/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update.

• Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

  7/28/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS) in individuals with stable schizophrenia on a stable, single, atypical antipsychotic regimen.

• Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors

  7/26/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25.

• Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

  6/28/2022

  Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients.

• Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

  6/22/2022

  Cyclerion Therapeutics, Inc. will participate in a webinar hosted by the United Mitochondrial Disease Foundation (UMDF) on Tuesday, June 28th at 8 a.m. EDT with a live Q&A.

• Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

  6/17/2022

  Cyclerion Therapeutics, Inc. today announced research from preclinical studies demonstrating treatment with its lead soluble guanylate cyclase (sGC) stimulator, CY6463, was associated with improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease.

• Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

  6/10/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data in its signal-seeking clinical study of CY6463.

• Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

  6/6/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2022 Symposium taking place June 8-11, 2022, in Phoenix, Arizona.

• Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

  5/4/2022

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced clinical development progress for CY6463, its lead program, and first quarter 2022 financial results.

• Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

  2/24/2022

  Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced clinical development updates for CY6463, its lead program, and additional corporate progress.

• Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

  2/23/2022

  Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration.